The Inflammation Biology Group’s overall objective is to facilitate the development of new treatment options for human diseases by exploiting basic research advances in inflammation biology.
The group has >20 years of activity in improving our understanding of the pathogenesis and clinical management of the arthritic diseases cause by alphaviruses such as chikungunya virus and Ross River virus. The group developed the first adult wild-type mouse model of chikungunya virus arthritis, which continues to be used by collaborators and biotech companies to test potential new interventions (eg vaccines and anti-inflammatory drugs).
The search for the physiological role of SerpinB2 (aka PAI-2) in inflammatory disease has been a major theme of the laboratory for many years. SerpinB2 is strongly up-regulated during many forms of inflammation, and a number of inflammatory diseases (eg preeclampsia, asthma, scleroderma, lupus) are associated with SerpinB2 polymorphisms or expression dysregulation. We are currently exploring the role of microparticle-associated SerpinB2.
A recent new initiative is the investigation of the role of the stress protein Sin1 in the drug sensitivity of pancreatic cancer, a process that appears to be linked to inflammation signalling.
Translation, generation and development of intellectual property, and advancing Australian biotech continue to be a key objective for the group. In the last 12 years the group has undertaken ≈ AU$3 million of collaborative contract R&D (32 contracts) with 12 companies (four international, eight Australian). The group produced 17 patents; 15 were commercialised, 12 remain active. Seven patents cover the new topical anti-cancer drug, ingenol mebutate/Picato (Leo Pharma), which was approved in 2012 in the US, Australia and Europe for treatment of actinic keratoses (precursors of skin cancer). One patent covers Cpn10 (Invion Ltd), recently tested in rheumatoid arthritis patients.
- Why vaccinate? (PDF): Woodford presentation.
- Research and development on chikungunya (PDF): Article in International Innovation.
- As humanity destroys the planet, will the planet fight back with disease or will it be concreted over before it gets the chance? (PDF): Woodford presentation.
- Biological agents in war and terror (PDF): Woodford presentation.
- Queensland researchers fight to repel new mozzie threat: ABC 730 Report.
- Biomedical Biotech Research in Queensland (PDF): Austrade’s BioLuncheon Series, EMBL, Heidelberg, Germany, 27 Nov 2012.
Group Leader: Professor Andreas Suhrbier
- Dr Wayne Schroder, Senior Research Officer
- Penny Rudd, Affiliate
- Lee Major, Research Officer
- Thuy Le, Research Assistant
If you wish to apply for QIMR Berghofer's student program,
click here for more information.